Amneal Pharmaceuticals beats top-line and bottom-line estimates; raises FY26 outlook
· seekingalpha.com
Amneal Pharmaceuticals (AMRX) Q2 2026 results: Non-GAAP EPS beat, revenue up 9.8% YoY and EBITDA +12%.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...